AGEN 1571
Alternative Names: AGEN-1571Latest Information Update: 28 Aug 2025
At a glance
- Originator Agenus
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Leukocyte immunoglobulin-like receptor B1 antagonists; Natural killer cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Aug 2025 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in USA (IV)
- 28 Aug 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy) in USA (IV)
- 23 Dec 2024 Agenus completes a Phase-I trial in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Combination therapy) in USA (NCT05377528)